Shree Ganesh Remedies profit and loss

Latest FY26

Revenue: ₹109cr+0.6% on FY25
EBITDA: ₹35.0cr−10.7% on FY25
Net profit: ₹17.8cr−23.1% on FY25
EPS: ₹13.84−23.0% on FY25

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

Expenses
	109	109	126
	3.0	3.7	3.1
	112	112	129
	40.9	37.4	61.0
	0.0	0.0	1.3
	1.0	−1.5	−4.9
	11.4	10.1	8.4
	3.6	2.1	0.6
	10.5	9.6	6.1
	21.0	23.4	18.2
	88.3	81.0	90.8
	35.0	39.2	41.8
	24.5	29.6	35.7
Profit
	24.0	31.3	38.2
	5.6	8.0	9.3
	0.5	−0.0	0.7
	6.2	8.2	10.1
	17.8	23.1	28.1
	0.0	−0.0	0.1
	17.8	23.1	28.2
Per share
	₹13.84	₹17.98	₹22.35
	₹13.84	₹17.98	₹22.35
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	67.4	72.7	68.4
	61.7%	67.0%	54.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SGRL₹658.00

Shree Ganesh Remedies Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SHUKRAPHAR SUNLOCMcap ₹845 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Revenue from Operations	125.9	108.6	109.3
Other Income	3.1	3.7	3.0
Total Income	129.0	112.3	112.3
Expenses
+ Cost of Materials Consumed	61.0	37.4	40.9
+ Purchases of Stock-in-Trade	1.3	0.0	0.0
+ Changes in Inventories	-4.9	-1.5	1.0
+ Employee Benefit Expense	8.4	10.1	11.4
+ Finance Costs	0.6	2.1	3.6
+ Depreciation & Amortisation	6.1	9.6	10.5
+ Other Expenses	18.2	23.4	21.0
Total Expenses	90.8	81.0	88.3
EBITDA	41.8	39.2	35.0
EBIT	35.7	29.6	24.5
Profit
Pretax Income	38.2	31.3	24.0
+ Current Tax	9.3	8.0	5.6
+ Deferred Tax	0.7	-0.0	0.5
Tax Expense	10.1	8.2	6.2
Net Income	28.1	23.1	17.8
+ Other Comprehensive Income	0.1	-0.0	0.0
Total Comprehensive Income	28.2	23.1	17.8
Per Share
Basic EPS	22.35	17.98	13.84
Diluted EPS	22.35	17.98	13.84
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	68.4	72.7	67.4
Gross Margin %	54.37	66.97	61.68

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.